Background: The optimal local-anaesthetic (LA) dose for transversus-abdominis-plane (TAP) block is unclear. In this meta-analysis, we aimed to determine whether TAP blocks for Caesarean delivery (CD) with low-dose (LD) LA demonstrated non-inferiority in terms of analgesic efficacy, compared with high-dose (HD) LA. Methods: A literature search was performed for randomised controlled trials examining the analgesic efficacy of TAP blocks vs control after CD. The different dosing used in these studies was classified as HD or LD (bupivacaine equivalents >50 or 50 mg per block side, respectively). The pooled results of each dose group vs control were indirectly compared using the Q test. The primary outcome was 24 h opioid consumption. Secondary outcomes included 6 and 24 h postoperative pain scores, time to first analgesia, 6 h opioid consumption, opioid-related side-effects, and maternal satisfaction. Results: Fourteen studies consisting of 770 women (389 TAP and 381 control) were included. Compared with controls, the 24 h opioid consumption (milligram morphine equivalents) was lower in HD [mean difference (MD) 95% confidence interval (CI) e22.41 (e38.56, e6.26); P¼0.007; I
The transversus abdominis plane (TAP) block was first described by Rafi 1 
in 2001. After a Caesarean delivery (CD), TAP
blocks have been shown to play a valuable role in providing adjunctive analgesia for patients who are undergoing CD with spinal anaesthesia without intrathecal morphine (ITM), 2e5 and provide analgesic benefit to patients undergoing CD with general anaesthesia. 4, 6, 7 During pregnancy, enhanced sensitivity to local anaesthetics (LAs) as a result of altered physiology may increase the risk of LA systemic toxicity (LAST). 8, 9 Even when the recommended maximal allowable LA doses are adhered to, the minimum toxic plasma concentrations can still be exceeded. 8 There have been several published cases of toniceclonic convulsions in women receiving TAP block for CD. 9e11 However, utilising lower doses may compromise the analgesic efficacy of the block. The optimum dosing strategy balancing analgesic efficacy and LAST remains unclear. Whilst studies have explored TAP blocks in the nonobstetric population and suggested similar efficacy between lower doses and higher doses of LA, 12e15 few studies have directly compared post-CD analgesic outcomes after low-dose (LD) and high-dose (HD) LA for TAP blocks. 16 , 17 Singh and colleagues 16 concluded that in the presence of ITM, neither HD nor LD LA TAP decreased pain scores at 24 h, whilst another study demonstrated that LD LA TAP provided similar analgesia effects compared with a higher-dose LA. 17 This meta-analysis aimed to determine whether TAP blocks for CD with LD LA demonstrated non-inferiority in terms of analgesic efficacy, compared with HD LA. The primary outcome of the study was 24 h opioid (in milligram morphine equivalents) usage postoperatively.
Methods
For this meta-analysis, the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) recommendations were followed. 18 As there is no universally accepted definition for HD or LD LA doses for TAP blocks, we assigned the various doses used in different studies to the HD and LD groups as bupivacaine equivalents >50 and 50 mg per block side, respectively. This cut-off value was chosen to reflect the dosing strategy of bupivacaine 0.25%, 20 ml per side that is commonly administered in the clinical setting and in published research, to represent a lower-dose TAP block. We identified randomised controlled trials comparing either HD or LD (or both) single-shot TAP blocks compared with control (no block, placebo block) for postoperative CD analgesia. Studies were included if TAP blocks were performed in the intraoperative period carried out by either landmarkbased or ultrasound-guided (USG) techniques, and patients underwent either elective or emergency CD (or both) under spinal or general anaesthesia. Studies were excluded if they utilized catheter-based TAP blocks, did not use similar analgesic adjuvants or long-acting intrathecal opioids within study groups (e.g. intrathecal morphine in control group, but not TAP group), and if TAP blocks were compared with other regional block techniques (excluding spinal anaesthesia). Letters, abstracts, case reports, reviews, comments, editorials, cadaveric studies, animal studies, and studies in a language that the authors were unable to translate were also excluded. A consensus amongst all authors was sought to finalize the list of studies to be included in the meta-analysis. Bibliographies of included studies and relevant review papers were also manually searched to capture any other relevant studies that met the inclusion criteria that may not have been identified in the original database search. We also searched for and reviewed published abstracts, and where appropriate, the authors were contacted.
The risk of bias for included studies was assessed using the Cochrane Risk of Bias tool. 19 The quality of included articles was also evaluated using the Jadad score. 20 Data extraction was independently carried out by at least two individuals (S.C.N. and S.S.). A standardized collection form was used for data extraction. Any relevant outcome data common to more than one paper were used for analysis. Discrepancies were resolved by re-examining the original manuscript. When any uncertainty arose, all authors were consulted and a consensus achieved. Where data were reported in a clear graphical format, the reviewers extracted the data from the graphs. If the source data were unclear, attempts were made to contact the authors. The primary outcome was difference in cumulative 24 h opioid consumption (in milligram morphine equivalents) between the HD and LD TAP block groups. Secondary outcomes included 6 h opioid consumption; time to first analgesic request; 24 h postoperative pain scores at rest and on movement using pain rating scales; 6 h postoperative pain scores at rest and on movement using pain rating scales; opioid-related side-effects (nausea, vomiting, and pruritus); and patient satisfaction. In order to standardize analysis, opioids were converted to i.v. morphine equivalents (tramadol:morphine 10:1 21 and morphine oral:i.v. 2:1 22 ), and LA agents were converted to bupivacaine equivalents based on previously published ratios (ropivacaine:bupivacaine 1:0.6 23 and
Editor's key points
The authors systematically reviewed the literature regarding the analgesic efficacy of high-dose or lowdose transversus abdominis plane (TAP) blocks after Caesarean delivery. In the 14 studies considered (770 patients), both highand low-dose approaches appeared effective in reducing 24 h morphine consumption, but there was no apparent difference between the high-and low-dose techniques in this, or other, outcome measures. The authors suggest that the data support the use of low-dose TAP blocks, potentially reducing the risk of systemic local anaesthetic toxicity.
levobupivacaine:bupivacaine 1:1 24 ). Pain reported as visual, verbal, or numerical rating scales was converted to a 0-to 100-point scale (where 0¼no pain and 100¼worst pain imaginable). Postoperative nausea and vomiting (PONV) were defined in our analysis as any reported postoperative nausea or vomiting. When these data were reported over different time intervals rather than the entire duration of the study, the highest reported incidence over the study period was used for the analysis. When an individual study had more than two study arms for comparison, we included only the group that received a TAP block (vs control group) in observance with our inclusion criteria.
Statistical analysis
Data were analysed using the Review Manager software (RevMan, version 5.3.5; Nordic Cochrane Centre, The Cochrane Collaboration, Copenhagen, Denmark). Mean differences (MDs) and risk ratios with 95% confidence intervals (CIs) for primary outcome and 99% CIs for secondary outcomes were calculated using random effects modelling. We combined studies comparing HD TAP block vs placebo and those comparing LD TAP block vs placebo, and calculated a pooled effect size for each dose for the primary and secondary outcomes. An indirect comparison of the HD and LD subgroups was then performed using the Q test. Heterogeneity amongst the studies was evaluated using the I 2 statistic. To investigate the impact of heterogeneity amongst the included studies, we performed a number of sensitivity analyses for the primary outcome of 24 h opioid consumption by excluding studies that did not perform USG blocks, those that did not perform a sham TAP block, and those who did not use a postoperative multimodal analgesic regimen.
Results

Included studies
We retrieved all 20 shortlisted articles that were identified from the literature search. A PRISMA flow diagram outlining study selection is provided in Figure 1 . The retrieved articles *Included studies were subsequently examined by two authors (S.C.N. and S.S.) to assess the eligibility for inclusion in the meta-analysis. The excluded trials are listed in Supplementary Appendix 2.
Fourteen randomized controlled trials met our inclusion criteria. 6,7,16,25e35 A total of 770 patients were included in the final analysis: 389 patients in the TAP group and 381 patients in the control group. Attempts were made to contact 10 authors, and three authors responded. 6, 27, 34 The methodology for each included study is summarized in Table 1 . All TAP blocks were performed at the end of CD with the majority (10 studies) using USG to perform bilateral TAP blockade. 6,16,25,28e32,34,35 The comparator groups in 11 studies had saline-based TAP blocks performed, 16,25e32,34,35 and three studies did not perform TAP blocks on comparator groups. 6, 7, 33 Six included studies in this meta-analysis performed TAP blocks at mid-axillary line, 6, 25, 28, 30, 31, 35 four at the triangle of petit, 7, 26, 27, 33 one medial to mid-axillary line, 34 one along the mid-to anterior axillary line, 16 and two did not state the site of injection. 29, 32 Of the 14 studies, five utilized bupivacaine, 7, 27, 30, 33, 34 two utilized levobupivacaine, 6, 35 and seven utilized ropivacaine. 16, 25, 26, 28, 29, 31, 32 Eleven studies utilized predetermined doses of LA (ranging from 50 to 100 mg per block side of ropivacaine, 25, 29, 31, 32 or from 37.5 to 100 mg per block side of bupivacaine or levobupivacaine). 6,7,28,30,33e35 The three remaining trials utilized a weight-based dose of LA (range 0.75 to 1.5 mg kg À1 per block side of ropivacaine 16, 26 The concentrations of LA varied amongst studies, including ropivacaine (0.75% in one study, 26 0.5% in four studies, 16, 25, 28, 31 0.375% in one study, 29 and 0.25% in two studies 16, 32 ); bupivacaine (0.375% in two studies 27, 34 and 0.25% in three studies 7, 30, 33 ); and levobupivacaine (0.5% in one study 35 and 0.25% in one study 6 ). The LA concentrations [presented as mean (SD) bupivacaine equivalents; mg ml À1 ] were significantly greater in the HD group compared with the LD group [LD 2.2 (0.5) mg ml À1 ; HD 3.6 (0.8) mg ml À1 ; P¼0.0009].
Six studies were excluded from the primary-outcome analysis, as there were no data on the 24 h opioid consumption. 16, 27, 29, 31, 34, 35 These studies were included in the secondary-outcome analyses. In one study, 34 two of the three arms of the trial were analysed because the excluded arm utilized clonidine as an adjuvant in the TAP block. Thirteen out of the 14 studies included only elective CD patients, and one study recruited elective and Category 3 CD (as defined by the 2010 Royal College of Obstetricians and Gynaecologists) patients. 6 Of the studies excluded, one we were unable to translate (Persian language), 36 one study was excluded because no inter-quartile range or SD data were available, 37 one was a non-randomized study, 38 one was a retrospective study, 39 and two were studies where the TAP group did not receive similar ITM as control group. 40, 41 Postoperative analgesia regimens varied amongst the included studies ( 31 The risk-of-bias assessment of the included studies is summarized in Figure 2 . The majority of trials demonstrated a low risk of bias. (Fig. 3) .
Primary outcome
Sensitivity analyses for the primary outcome
Because of the high heterogeneity demonstrated in the comparisons between the HD, LD TAP, and control groups, three additional sensitivity analyses were performed for the primary outcome of the 24 h opioid consumption (Supplementary Appendix 3): excluding studies that did not use USG (Subgroup A; n¼123), excluding studies that did not perform a sham TAP block (Subgroup B; n¼128), and excluding studies that did not use a multimodal regimen for postoperative analgesia (Subgroup C; n¼183). The analyses of Subgroups A, B, and C demonstrated no differences in the 24 h opioid consumption between the HD and LD TAP groups [Subgroup A: HD MD 95% CI e14.14 (e17.15, e11.14), LD e18. 14 
Secondary outcomes
Additional analgesic outcomes (6 h opioid consumption, time to first analgesic request, and 24 and 6 h pain scores at rest and on movement), maternal side-effects (PONV and pruritus), and maternal satisfaction are summarized in Table 3 . There were no differences between the HD and LD groups for any of these outcomes. There were no serious local complications associated with the TAP block. However, there was one TAP study patient that had an anaphylactoid reaction after receiving the study solution of ropivacaine 0.5%, 20 ml. 25 
Discussion
Based on indirect comparisons between the HD and LD TAP blocks, this meta-analysis demonstrates no difference in postoperative opioid consumption or pain scores after CD. This suggests that there may be no additional analgesic benefit in performing HD compared with LD TAP blocks for CD. TAP blocks are used in current clinical practice to provide Postop Triangle of petit Postop Mid-axillary
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additional analgesia after CD. Whilst the addition of TAP blocks does not offer improved analgesia for CD under spinal anaesthesia when using ITM, 2,4,5,42 meta-analyses have shown benefit when TAP block is used in conjunction with spinal anaesthesia without long-acting opioids or when patients undergo general anaesthesia for CD. To our knowledge, this is the first meta-analysis examining the impact of HD vs LD TAP blocks on postoperative analgesia requirements and pain scores after CD. The factors that may affect analgesia provided by TAP blocks include location of injection, landmark vs USG, and LA administered (including drug, total dose, concentration, and volume). The variations in these factors may account for the large heterogeneity demonstrated between the studies included in this meta-analysis. The pattern of spread of LA differs, depending on the site of injection into the TAP, which may have important implications for the extent of analgesia produced with each approach. Carney and colleagues 43 demonstrated differences in LA spread in healthy volunteers by utilising magnetic resonance imaging (MRI) and contrast, and four different TAP techniques. The anterior subcostal and mid-axillary approaches resulted in a predominantly anterior spread within the TAP and relatively little posterior spread. There was no spread to the paravertebral space with the anterior subcostal approach. The mid-axillary TAP block resulted in minimal contrast enhancement in the paravertebral space at T12 to L2. In contrast, the posterior approaches resulted in a predominantly posterior spread around the quadratus lumborum to the paravertebral space from T5 to L1 vertebral levels. 43 Cadaveric TAP block studies utilising MRI have also demonstrated that sensory block extension from T7 to L1 gradually recedes over 4e6 h with lidocaine 0.5%. 44 Landmark techniques using the triangle of Petit, generally regarded as the posterior approach for TAP blocks, result in injectate spread posteriorly to the thoracolumbar paravertebral space. 43 The potential blockade of the sympathetic chain in the paravertebral space may explain the prolonged analgesia seen with the posterior approach compared with lateral approaches commonly seen with USG techniques. 45 With the introduction of ultrasound technology, the different layers of the abdominal wall are easily identified in real time, promoting various descriptions of TAP block injection points. 46e48 Whilst these techniques provide analgesia to the anterolateral abdominal wall, their efficacies may not be equal because of the location of injection into the TAP that facilitates a different pattern of LA spread between the abdominal wall muscles. 43, 44, 49 In a study of surgical patients undergoing inguinal hernia repair, the patients were randomized to receive TAP block either with bupivacaine 0.125% or 0.25%, 20 ml. 12 The study demonstrated no difference between groups with pain scores (visual analogue scale), time to first morphine requirement, and 24 h morphine consumption. In obstetrics, Singh and colleagues 16 performed a dose-ranging study evaluating the effect of TAP LA dose on analgesia in patients also receiving intrathecal morphine. The authors observed a significant reduction in pain scores with movement at 6 and 12 h in the HD group (ropivacaine 3 mg kg À1 ) compared with LD (ropivacaine 1.5 mg kg
À1
), but no difference at 24 h. Few randomized studies and no meta-analyses have explored the analgesic effects of LA dose, volume, or concentration utilized for TAP blocks in CD patients. Two meta-analyses examined TAP blocks in all types of abdominal surgery, and included LA dose and LA volume influence in their review. 42, 50 Abdallah and colleagues 50 demonstrated a trend towards superior analgesia with !15 ml of LA per side of block, which may be attributable to improved LA spread associated with larger volumes. However, when dividing groups into dilute (ropivacaine 0.2% and bupivacaine 0.25%), intermediate (ropivacaine 0.375%, bupivacaine 0.375%, and levobupivacaine 0.375%), concentrated (ropivacaine 0.5%, bupivacaine 0.5%, and levobupivacaine 0.5%), and highly concentrated (ropivacaine 0.75%) solutions, they were unable to demonstrate an effect of LA concentration on analgesia. In this meta-analysis, the LA dose varied between the HD and LD groups because of differences in the LA concentration rather than the LA volumes administered. The LA volumes were not significantly different between the HD and LD groups, and so the effects of LA volume could not be explored. A recent review by Baeriswyl and colleagues 42 reported no additional opioid-sparing effect above a volume of 12 ml of LA per block side (total bupivacaine equivalent dose of 60 mg). Local anaesthesia in the truncal regional anaesthesia blocks may reach systemic threshold for LA toxicity. A recent meta-analysis demonstrated this by evaluating the systemic concentrations of LA after perioperative single-shot TAP or rectus sheath block, and demonstrated that 8.6% of patients had systemic concentrations that were above the commonly acceptable threshold for LAST. 51 The challenge facing anaesthesiologists caring for obstetric patients is to find a balance between utilising a LA that provides effective analgesia whilst minimising the risk of LAST. In pregnancy, enhanced sensitivity as a result of altered physiology may lead to an increased risk of LAST. LAST and blood concentrations of ropivacaine. Even when clinicians adhered to recommended maximum LA doses, the LA concentrations often exceeded minimum toxic plasma concentrations. 8 In these reports, the TAP LA dose ranged from 150 to 180 mg bupivacaine equivalents. Including Griffiths and colleagues, 8 these case reports would be classified as HD TAP blocks using our study definition. As LAST may even occur within the recommended maximal allowable LA doses, our results suggest that clinicians should utilize LD instead of HD TAP blocks to provide comparable analgesic efficacy whilst reducing the LAST risk. This meta-analysis has several limitations. There is no universally accepted definition for LD or HD for TAP blocks. Therefore, for this meta-analysis, we agreed to assign HD and LD of LA as bupivacaine equivalents >50 and 50 mg per block side, respectively. The authors feel that this value reflects the current clinical practice (e.g. our institutions utilize bupivacaine 0.25%, 20 ml per side), and utilising this cut-off value also allowed for balanced reporting amongst the available studies between the LD and HD subgroup analyses. Our result is based on indirect comparisons between the HD and LD groups, as studies rarely directly compared LD and HD groups. Therefore, it was not possible to perform a meta-analysis solely utilising studies performing direct comparisons between LD and HD. Similar to meta-regressions, indirect comparisons based on subgroup analyses are observational in nature, results therefore must be interpreted in the context of this limitation. We acknowledge the relatively small number of patients utilized for the primary-outcome analysis (8 studies; 203 patients). It is also evident from the heterogeneity of the study designs that there remains no consensus as to the most effective dose of LA for TAP block for CD. The studies utilized different LA drugs, LA doses, LA concentrations, LA volumes, and TAP techniques, and intra-and postoperative analgesic regimens. For analysis, equivalent dose conversions were carried out for the various types of LA and opioids used in included studies. This metaanalysis utilized the British National Formulary 22 conversion ratio for morphine. The authors acknowledge that the different conversion ratios between i.v. and oral morphine have been described (such as a 1:3 ratio), but this would not have changed the findings and conclusion of this study. We included studies with patients undergoing elective or emergency CD, and using both USG or landmark approaches. The accuracy of the landmark-based TAP blocks (utilized in 4 of the 14 studies in this meta-analysis) has been questioned with previous studies reporting only 25% ideal TAP block placement using this technique. 54, 55 Continuous and singleshot wound-infiltration techniques were excluded in this analysis. Published studies do indicate these techniques may be as efficacious as TAP blocks 11, 56, 57 ; however, there are few studies directly comparing these techniques, with some conflicting results. 58 The heterogeneity for the primary outcome of 24 h opioid consumption was high. Performing subgroup analyses did not affect heterogeneity and made no difference to the result for the primary outcome. We did not test for publication bias for the primary outcome, as only eight studies reporting this outcome were included and tests of publication bias are not recommended for analyses, including less than 10 studies. 59 Finally, it was not possible to acquire additional data from all included trials despite efforts to contact authors.
In conclusion, this meta-analysis found no significant differences in postoperative opioid use and pain after CD between HD and LD TAP blocks. Given the comparable analgesia, we recommend the use of LD TAP blocks (i.e. bupivacaine equivalents 50 mg per block side) in the CD setting in order to mitigate the potential risks of LAST in this at-risk population. Findings can reassure clinicians that LD TAP blocks can be utilized without compromising the analgesic efficacy of TAP blockade.
